Altimmune (ALT) CEO Jerome Durso purchases 15,000 shares at $2.95 each

Rhea-AI Filing Summary

Altimmune, Inc. President and CEO Jerome Benedict Durso purchased 15,000 shares of Altimmune common stock on 2026-08-13 in a purchase in open market or private transaction at $2.95 per share. Following this transaction, his directly held position increased to 62,500 shares of common stock.

Insider Trade Summary

Net Buyer: 15,000 shares

Net Buy 1 txn

Insider Durso Jerome Benedict

Role President and CEO

Bought 15,000 shs ($44K)

Type	Security	Shares	Price	Value
Purchase	Common Stock, par value $0.0001	15,000	$2.95	$44K

Holdings After Transaction: Common Stock, par value $0.0001 — 62,500 shares (Direct)

Key Figures

Shares purchased: 15,000 shares Purchase price: $2.95 per share Shares held after transaction: 62,500 shares

3 metrics

Shares purchased 15,000 shares Common Stock purchased on 2026-08-13

Purchase price $2.95 per share Price for the 15,000-share purchase on 2026-08-13

Shares held after transaction 62,500 shares Directly owned Altimmune common stock post-transaction

Key Terms

purchase in open market or private transaction, Common Stock, par value $0.0001, direct ownership

3 terms

purchase in open market or private transaction financial

"Described as a purchase in open market or private transaction at $2.95"

Common Stock, par value $0.0001 financial

"Security title listed as Common Stock, par value $0.0001"

direct ownership financial

"Ownership code D indicates direct ownership of the shares"

FAQ

What insider transaction did Altimmune (ALT) report for Jerome Benedict Durso?

Altimmune reported that President and CEO Jerome Benedict Durso purchased 15,000 shares of common stock on 2026-08-13. The shares were acquired in a purchase in open market or private transaction at $2.95 per share.

At what price did the Altimmune (ALT) CEO buy shares in this Form 4?

Jerome Benedict Durso bought Altimmune common stock at $2.95 per share. The Form 4 describes the transaction as a purchase in open market or private transaction involving 15,000 shares of common stock.

How many Altimmune (ALT) shares does the CEO hold after this reported transaction?

After the reported transaction, Jerome Benedict Durso directly holds 62,500 shares of Altimmune common stock. This reflects the addition of 15,000 shares purchased on 2026-08-13 as disclosed in the Form 4.

Was the Altimmune (ALT) CEO’s 15,000-share purchase under a Rule 10b5-1 plan?

The Form 4 does not affirm that the CEO’s 15,000-share purchase was made under a Rule 10b5-1 trading plan. The filing’s Rule 10b5-1 checkbox is marked as false, indicating no such affirmation for this transaction.

Is the Altimmune (ALT) CEO’s ownership in this Form 4 direct or indirect?

The Form 4 shows the CEO’s ownership as direct. The transaction and post-transaction holdings of 62,500 shares are reported with ownership code "D", indicating direct ownership rather than indirect through another entity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/13/2026 - 04:06 PM Accepted by SEC EDGAR 08/13/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Durso Jerome Benedict

(Last) (First) (Middle)

910 CLOPPER ROAD

SUITE 201S

(Street)

GAITHERSBURG MARYLAND 20878

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Altimmune, Inc. [ ALT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001	08/13/2026		P		15,000	A	$2.95	62,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Gregory Weaver, as Attorney-in-Fact	08/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)